Proenkephalin gene regulation in the paraventricular nucleus by GABA: interactions with opioid systems in a transgenic model.
GABA, which is present at high levels within the paraventricular nucleus (PVN) of the hypothalamus, has been implicated in neuroendocrine regulation. Here we use a transgenic mouse model expressing a human proenkephalin-beta-galactosidase fusion gene, in which both up-regulation and down-regulation of gene expression can be measured easily, to study the effects of GABA on basal and stress-induced gene expression within the PVN. This model has been shown previously to be appropriately physiologically regulated by stress within the PVN. Acute systemic administration of GABA, of aminooxyacetic acid, and of the selective GABA(B) receptor agonist, baclofen, induces transgene expression in the PVN. Chronic administration of aminooxyacetic acid inhibits both basal and stress-induced transgene expression. Acute or chronic administration of the selective GABA(A) agonist, muscimol, inhibits both basal and stress-induced expression of the transgene. Muscimol also inhibits transgene expression in hypothalamic slice cultures in which extrahypothalamic afferents are removed. It is surprising that, following chronic aminooxyacetic acid administration, the opiate antagonist naltrexone induces transgene expression in a manner similar to that observed with naloxone-precipitated opioid withdrawal and that expression is accompanied by a behavioral syndrome that partially mimicks opioid withdrawal. Taken together with our previous work, and using gene expression as our read-out, we conclude that transgene-expressing PVN neurons receive tonic inhibitory inputs mediated via GABA(A) receptors. Moreover, these inhibitory inputs can themselves be inhibited via GABA(B) and mu-opioid receptors.
Borsook
D
D
Neuronal Plasticity Research Group, and Department of Anesthesia and Critical Care, Massachusetts General Hospital, and Harvard Medical School, Boston 02129, USA.
Falkowski
O
O
Smirnova
O
O
D000625:Aminooxyacetic Acid / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured; D004745:Enkephalins / Q000096:biosynthesis* / Q000235:genetics; D058785:GABA-A Receptor Agonists; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D009118:Muscimol / Q000494:pharmacology; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009924:Organ Culture Techniques; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism*; D011498:Protein Precursors / Q000096:biosynthesis* / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D012462:Saline Solution, Hypertonic; D013312:Stress, Physiological; D001616:beta-Galactosidase / Q000096:biosynthesis; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000502:physiology*
D004745:Enkephalins; D058785:GABA-A Receptor Agonists; D009292:Narcotic Antagonists; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; D012462:Saline Solution, Hypertonic; C029992:proenkephalin; D000625:Aminooxyacetic Acid; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; D009271:Naltrexone; D001616:beta-Galactosidase